Navigation Links
Small Business Innovation Research Program Awards Grant to Biomoda
Date:6/25/2008

Company developing proposals to fund clinical studies for early detection

of lung cancer

ALBUQUERQUE, N.M., June 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, announced it has received a grant from the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) seed grant programs to develop proposals for funding of clinical studies using its proprietary testing technology for detection of early lung cancer.

"We're very enthusiastic about the opportunity this capital offers for continued development of various aspects of our portfolio of non-invasive, early stage cancer detection technologies," said Biomoda Government Affairs Advisor Bruce Donisthorpe. "The funding further validates the potential of our innovative technology, particularly the broad-scale benefits expected to accrue from its commercialization."

The SBIR and SBTT's Phase 0 Program provides technology businesses with the opportunity to propose innovative ideas that match research and development needs of 11 participating federal agencies, including the Departments of Homeland Security, Agriculture, Commerce, Defense, Education, Energy, Transportation, Health and Human Services, National Aeronautics and Space Administration, Environmental Protection Agency, and the National Science Foundation.

Biomoda's technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding.

Lung cancer claims more lives than any other cancer. The expected five- year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

Biomoda's technology was originally developed at Los Alamos National Laboratory.

Contact: John Cousins

505-821-0875

investor@biomoda.com

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
2. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Albemarle Optimizes Smallpox Drug Candidate for SIGA
5. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
6. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
8. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
9. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre (SCHC), ... Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a ... the Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among ... all types and genders. And the need for advanced services is growing. , ... top-rated cancer care program, in collaboration with their non-profit partners in their fight against ...
(Date:2/26/2017)... Ireland (PRWEB) , ... February 26, 2017 , ... ... as in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 ... 1 (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... patients after receiving cognitive rehabilitation, according to a study released today at the ... that cognitive rehabilitation programs are proven to be effective in improving cognitive function ...
Breaking Medicine News(10 mins):